Moving Beyond JAK Inhibitors in Myeloproliferative Neoplasms

1 意见
administrator
administrator
07/29/23

Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.

  • 类别

显示更多

0 注释 排序方式

没有找到评论

脸书评论

下一个